The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Key takeaways from the iStopMM trial: screening for MGUS
In this video, Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavík, Iceland, discusses key takeaways from the iStopMM trial (NCT03327597), which assessed the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). A new subgroup of MGUS known as light-chain MGUS has been redefined, and this study has also allowed for the earlier diagnosis of multiple myeloma. Importantly, screening has not had a negative impact on the mental health of individuals. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
